OTC, Pharmaceutical, Nutritional, & Biotech Stocks

[harr449]

TY for info.

[FELLER]

OWCP is a Cannabis pharmaceutical company in research and development stage, but with products expected out in early 2017. They have 8 patents and already had an offer to acquire them last year.

Buying now, below $0.20/share, is likely to be a GIFT come 2017...

Read some of the DD at www.OwnTheFloat.com

[harr449]

I kept it so far.

[harr449]

A post to keep my Mod. job.

[harr449]

ILNS 02/10/2015 09:23:40 Reverse Split/Cusip Change

02/11/2015 ILNS Intellect Neurosciences, Inc. Common Stock Other OTC

http://otce.finra.org/DailyList

[joe_techi]

NVLX - 7/16/14 price about 27 cents. Nuvilex has a drug delivery technology which is innovative, effective, technologically advanced, causes less side effects, and is flexible across a broad spectrum of ailments. Nuvilex has Dr. Von Hoff and Dr. Matthias Löhr on their team, two leading pancreatic/tumor cancer specialists (google them). Nuvilex has the licensing agreements to patented technology (cell in a box). They have everything ready to capture major segments of this market (pancreatic cancer, pain, tumors, diabetes, etc). Investors right now are just early to the party, people are learning about Nuvilex as we speak...after pre-clinical (Aug 2014) and start of Phase 2b clinical (early 2015), the real show will start in my opinion.

[harr449]

Hello

[harr449]

Apr 17 Intellect Neurosciences, Inc. (ILNS)

OtcWizard, Penny PayDay, MadPennyStocks, PennyStockVille, CoolPennyStocks, Stock Rich, SmallCapStockPlays, StockEgg, PennyInvest, BullRally, HotOTC, and OTCPicks reported earlier on Intellect Neurosciences, Inc. (ILNS), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB listed Intellect Neurosciences, Inc. is a biopharmaceutical company based in New York, New York. It is developing and advancing a patent portfolio related to specific therapeutic approaches for treating Alzheimer's disease (AD). The Company is also developing proprietary drug candidates to treat AD and other diseases associated with oxidative stress. Intellect Neurosciences’ central business strategy is the licensing of its intellectual property (IP) and development of innovative therapeutics that it has purchased, developed internally, or in-licensed from universities and others.

Intellect looks to complete human proof of concept (Phase II) studies and subsequently enter into collaboration agreements, licenses or sales to complete product development and commercialize the resulting drug products. Its intention is to reap revenues from licensing fees, milestone payments, development fees, royalties and/or sales related to the use of its drug candidates or IP for specific therapeutic indications or applications. The Company’s current business centers on granting licenses to its patent estate to large pharmaceutical companies and on R&D of proprietary therapies for the treatment of AD through outsourcing and other arrangements with third parties.

Intellect’s pipeline includes drugs based on its immunotherapy platform technologies, ANTISENILIN and RECALL-VAX. The basis of these immunotherapy programs are on monoclonal antibodies and therapeutic vaccines, respectively, to prevent the accumulation and toxicity of the amyloid beta toxin. Both are in pre-clinical development. Intellect’s lead product candidate in its immunotherapy programs is IN-N01. This is a monoclonal antibody that has undergone particular procedures in the humanization process at MRCT in the UK.

Neurosciences’ most advanced drug candidate is OX1. This is a chemically synthesized form of a small, potent, dual mode of action, naturally occurring molecule. The Company granted an exclusive license to ViroPharma, Inc. in September of 2011, regarding certain of Intellect Neurosciences licensed patents and patent applications related to OX1. It transferred to ViroPharma all of its data and knowledge related to OX1 in exchange for payment by ViroPharma of a $6.5 million up-front licensing fee and additional regulatory milestone payments based upon future defined events in the United States and the EU. ViroPharma expects to develop and commercialize OX1 as a treatment of Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.

This past January, Intellect announced that it obtained a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent allowance is for TOC-1. This is a monoclonal antibody that selectively binds neurotoxic pre-fibrillar tau aggregates that are important pathological components in AD and other neurodegenerative tauopathies. Intellect Neurosciences previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement with Northwestern University.

Intellect Neurosciences, Inc. (ILNS), closed Wednesday's trading session at $0.008, down 11.11%, on 1,923,877 volume with 35 trades. The average volume for the last 60 days is 2,172,792 and the stock's 52-week low/high is $0.0041/$0.013.

http://qualitystocks.net/newsletter/newsletter.html

[harr449]

PMBS had a decent run, falling off?

[Adoni$74]

PMBS going to be huge this week! 10Q coming out on the 15th with revenues and sales numbers, product has been on shelves across America!!

Look for a huge breakout starting this week ;)

[harr449]

PMBS charts:

http://stockcharts.com/h-sc/ui?s=PMBS&p=D&yr=0&mn=3&dy=0&id=p79563651346

http://stockcharts.com/h-sc/ui?s=PMBS&p=D&yr=0&mn=3&dy=0&id=p30348300118

http://stockcharts.com/h-sc/ui?s=PMBS&p=D&yr=0&mn=3&dy=0&id=p85259438061

[Donner]

PMBS 129mil .0046 .008 .012 .015

"Load & Hold!" That's what everyone else has been doing! PMBS has been loaded for a week now and is soon ready to run!

Product on the shelves at CVS

Real product real company with the low share structure it's good for .01+ on it's own but one mention of entering the Marijuana sector or developing a Marijuana based product and it's multi pennies in no time!

Get those bids in low but don't wait too long for a couple ticks lower it may turn into 4-5 ticks higher real fast!

Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Dec 31, 2007

Incorporated In: MN, USA
Year of Inc. 2006

PMBS Security Details
Share Structure
Market Value1 $246,780 a/o Feb 07, 2014
Shares Outstanding 129,884,289 a/o Dec 31, 2013
Float Not Available
Authorized Shares 1,000,000,000 a/o Sep 30, 2013
Par Value 0.001

Shareholders
Shareholders of Record 317 a/o Oct 15, 2013

http://www.otcmarkets.com/stock/PMBS/company-info

[harr449]

Many stocks in the Info. box did good last month.

For some reason, those same stocks are declining in price this month.

GNVC went from just above a dollar in Nov. 2013 to over $4 last month. It too is falling off this month.

[harr449]

19-Nov-2013 Form 10-Q for INTELLECT NEUROSCIENCES, INC.

http://biz.yahoo.com/e/131119/ilns10-q.html

[harr449]

RXPC Time & Sales

Price Size Mkt Time
$0.0001 1,000,000 OTO 12:15:12
$0.0001 769,640 OTO 12:14:18
$0.0001 230,500 OTO 12:14:18

[Big_Money_Upward]

RXPC .0001 ===> .0007/share lawsuit settlement?

[harr449]

GNVC - GenVec announced that the previously disclosed putative class action lawsuit filed against the company and certain of its current and former officers by the law firm of Brower Piven in the United States District Court for the District of Maryland has been dismissed with prejudice. No payment was made by any of the Defendants to the plaintiffs or their counsel in connection with the lawsuit. The Company does not know whether the plaintiffs will file a Notice of Appeal.

http://finance.yahoo.com/news/genvec-announces-dismissal-class-actoin-115953208.html

[harr449]

GNVC - Up 48%, Big news recently.

http://ih.advfn.com/p.php?pid=squote&symbol=GNVC

[harr449]

MSLP recent headlines:

MusclePharm Down 15%, But It'll Be Backat Seeking Alpha(Thu 8:45AM EDT)
MusclePharm's CEO Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Aug 14)
MUSCLEPHARM CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, Aug 14)
MusclePharm Second Quarter Gross Sales Increased 51% to a Record $28.5 MillionMarketwired(Wed, Aug 14)
MUSCLEPHARM CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Aug 14)
The Frost Group, LLC Leads $2.5 Million Investment in MusclePharmMarketwired(Mon, Aug 12)
MUSCLEPHARM CORP Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Aug 9)

http://finance.yahoo.com/q?s=MSLP

[harr449]

MSLP Aug. 7, 2013 MusclePharm's Popular Combat Protein Powder® To Be Available At Costco Nationwide

http://finance.yahoo.com/news/musclepharms-popular-combat-protein-powder-113000764.html

[harr449]

ILNS - Intellect Neurosciences Retains Chain Pharmaceuticals LLC

NEW YORK, July 30, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.

"We are delighted Dr. Daniel Chain has agreed to return to Intellect as a consultant and assist us with our strategic options," said Elliot M. Maza, Consulting Chief Financial Officer and Director of Intellect Neurosciences. "As the founder of Intellect, Dr. Chain is uniquely qualified to assist us in our efforts to maximize the value of Intellect's unique collection of high value assets."

About Intellect Neurosciences

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.

http://finance.yahoo.com/news/intellect-neurosciences-retains-chain-pharmaceuticals-153000033.html

[harr449]

Jun 20, 2013 Intellect Neurosciences, Inc. Issues Letter to Shareholders

http://finance.yahoo.com/news/intellect-neurosciences-inc-issues-letter-132547041.html

[harr449]

Still following stocks on this board.

[harr449]

GNVC Form 8-K for GENVEC INC

28-May-2013

Other Events

Item 8.01. Other Events.

On May 24, 2013, GenVec's Board of Directors approved a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution"), subject to stockholder approval. The Company's Board of Directors has concluded, after extensive and careful consideration of the Company's strategic alternatives and the terms and conditions of the Plan of Dissolution, that the liquidation and dissolution of the Company, pursuant to the Plan of Dissolution, is in the best interests of the Company and its stockholders.

If the Company's stockholders approve the Plan of Dissolution, the Company plans to file a certificate of dissolution with the Delaware Secretary of State, complete the liquidation of the Company's assets, satisfy the Company's remaining obligations and make distributions to the Company's stockholders of any available liquidation proceeds. Following stockholder approval of the Plan of Dissolution and the filing of the certificate of dissolution, the Company would delist its common stock from NASDAQ.

The Company may abandon the Plan of Dissolution if the Board of Directors determines that, in light of new proposals presented or changes in circumstances, liquidation and dissolution pursuant to the Plan of Dissolution are no longer advisable and in the best interests of the Company and its stockholders.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

The Company plans to file with the SEC and mail to its stockholders a Proxy Statement in connection with the proposed liquidation and dissolution. The Proxy Statement will contain important information about the Company, the proposed liquidation and dissolution and related matters. Investors and stockholders are urged to read the Proxy Statement carefully when it is available. Investors and stockholders will be able to obtain free copies of the Proxy Statement under Schedule 14A and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of the Proxy Statement from the Company by contacting the Corporate Secretary of GenVec, Inc. at [phone].

http://biz.yahoo.com/e/130528/gnvc8-k.html

[harr449]

TY DOLLARLAND.

[DOLLARLAND]

ADIA Nutrition put out some very impressive news this morning. Products to be sold in nearly 200 Albertson's locations, in addition to the Whole Foods locations they're already in:

http://ih.advfn.com/p.php?pid=nmona&article=56271988

Chart is also setting up nicely for a potential breakout:

[harr449]

Some stocks in iBox have increased nicely.

MSLP
http://stockcharts.com/c-sc/sc?s=MSLP&p=D&yr=0&mn=3&dy=0&i=p64009539059&r=3946

KBLB
http://stockcharts.com/c-sc/sc?s=KBLB&p=D&yr=0&mn=3&dy=0&i=p92786351373&r=328

GNVC
http://stockcharts.com/c-sc/sc?s=GNVC&p=D&yr=0&mn=3&dy=0&i=p38331321939&r=8254

[harr449]

RE: MLXO. I'm a normal shareholder and a normal stock investor.

I've never personally met or talked by phone to former or present Michelex management. My communication has been thru emails.

I signed a confidentiality agreement with Michelex months ago for the purpose of reviewing draft documents to be released to MLXO shareholders. Since I've been a long term shareholder in this stock, I was asked to comment on the validity of detailed, factual information in some draft documents.

That is the limit of my association with Michelex.

I read the MLXO board and find it odd that some posters would think I'm part of a scam and wonder where the pumper went. I stated on the board that I wouldn't post again until management released something for public viewing. My absence cost me my moderator position.

Feel free to post this message if anyone reads it.

[harr449]

"The shares of Hire International undergone a symbol change and reverse split as of 11/19/12".

Email posted on IHUB board.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=81913598

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=81643650&txt2find=tlan

[harr449]

TLAN Deleted Symbol:

http://ih.advfn.com/p.php?pid=nmona&article=55099440

http://investorshub.advfn.com/Trulan-Resources-Inc-TLAND-14705/

[harr449]

MSLP Reverse Split: 11.26.12

http://investorshub.advfn.com/Muscle-Pharm-Corporation-MSLPD-17013/

[harr449]

Missed what happened to MSLP & TLAN.

Those tickers appear to be obsolete.

[harr449]

MLXO Darshan Shah

https://docs.google.com/viewer?a=v&q=cache:3KlS1EklxnEJ:w3.health.state.ny.us/opmc/factions.nsf/0/af55ed54ec2f06c785256a4a0047ee61/%24FILE/lc128759.pdf+&hl=en&gl=us&pid=bl&srcid=ADGEESi_JC0h_DXlhZYV-63XiA9_CbN8QKU1g30KooYJ6CLQxdwM5r43yiWid1_mKcot7cI_SmRs7LyxaYjAKVvam_7TSKaSad739-MgOJTO-TZrD_phfCPaPvu2G2-xXYstFCrsM3b8&sig=AHIEtbSNc9Jr0Se2dTX9s0NlSrhq69Lh6Q

[harr449]

ADMP technically looks strong.

It's price has doubled since late Sept.

http://stockcharts.com/h-sc/ui?s=ADMP&p=D&yr=0&mn=3&dy=0&id=p70524504172

[harr449]

SZYM technically looks weak right now.

http://stockcharts.com/h-sc/ui?s=SZYM&p=D&yr=0&mn=3&dy=0&id=p97422303561

[harr449]

lol, you're right.

[chirmpenholder]

I hear you in one sense; in another, though, stocks are about percentage gains, not price, right? If you have $1000 to invest, all you care about is a 25% gain, not the number of shares you own.

[harr449]

SZYM, I can't afford it.

Thank you anyways.

[harr449]

ADMP, nice rise in price since Feb. 2012.

Recent filing authorizes increase in authorized shares.

[harr449]

thanx. will check them out.

[chirmpenholder]

I recommend ADMP and SZYM for your consideration, Harr.

[harr449]

It's been awhile. Technically, charts in iBox don't show any stocks

to show immediate promise.

[harr449]

KBLB Kraig Biocraft Laboratories Announces New Laboratory Opening during Shareholder Conference Call

http://finance.yahoo.com/news/kraig-biocraft-laboratories-announces-laboratory-100500065.html

[harr449]

MSLP MusclePharm Opens Office in Canada, Part of Global Expansion of the Brand

http://finance.yahoo.com/news/musclepharm-opens-office-canada-part-142800026.html

[harr449]

ILNS Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN® Alzheimer's Disease Immunotherapy Technology Platform

USPTO allows claims directed to methods of treating Alzheimer's disease using therapeutic antibodies that recognize the free C-terminus of Beta Amyloid 1-40

http://finance.yahoo.com/news/intellect-neurosciences-receives-notice-allowance-133000163.html

[harr449]

GNVC - The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in GenVec, Inc. of Class Action Lawsuit and the Deadline of April 6, 2012 to Seek a Lead Plaintiff Position

http://finance.yahoo.com/news/The-Law-Firm-Levi-Korsinsky-bw-4025503234.html?x=0

[harr449]

Why do I sometimes see $ before ticker?

[EliotWings]

$MCLN 45,195,357

[harr449]

GNVC GenVec to Present at the 14th Annual BIO CEO & Investor ConferencePR Newswire(Tue 8:15AM EST)

Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.PR Newswire(Mon, Feb 6)

Brower Piven Files Class Action Suit Against GenVec, Inc.Marketwire(Fri, Feb 3)

GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD DisclosureEDGAR Online(Fri, Jan 27)

GenVec Extends Research Collaboration with Global Pharmaceutical CompanyPR Newswire(Fri, Jan 27)

http://finance.yahoo.com/q?s=GNVC

[harr449]

KBLB Kraig Biocraft Laboratories Featured in Current Issue of Textile World

http://finance.yahoo.com/news/Kraig-Biocraft-Laboratories-iw-2795414298.html?x=0